Pushing the envelope through health innovation
Sponsored by the CSG Health Public Policy Committee
Friday, Sept. 20, 9-11 a.m.
The explosion of innovation has the potential to change the face of medicine, improving lives along the way. Speakers will trace the path of new medications from discovery in the laboratory to successful commercialization by private-sector companies to life-saving treatment in health care settings. Panelists will discuss the role public policies can play to encourage, support and facilitate innovation.
This session will take place at the University of Kansas Cancer Center. Buses will depart promptly at 8:30 a.m. from the south side of Pershing in front of the Westin.
All conference attendees are invited to attend, however additional registration for this session is required. The session will be limited to the first 100 participants. Forms must be received by noon, Thursday, Sept. 19.
Richard H. Bagger
Senior Vice President, Corporate Affairs and Strategic Market Access, Celgene Corporation
Roy A. Jensen, MD
Director, The University of Kansas Cancer Center
President and CEO, The University of Kansas Hospital
Rich Bagger is responsible for advancing patient access to Celgene therapies for cancer and severe, immune-inflammatory conditions and driving recognition of the value of Celgene innovation through government relations, communications, patient advocacy and market access policy activities around the world.
He most recently served for two years as Chief of Staff for New Jersey Governor Chris Christie, responsible for managing implementation of the Governor’s policy agenda and priorities. He served ten years in the New Jersey General Assembly, where he was Chairman of the Appropriations Committee and Majority Conference Leader, and two years in the New Jersey Senate.
He received an A.B. degree from Princeton University’s Woodrow Wilson School of Public and International Affairs and a J.D. degree from Rutgers University Law School.
Roy A. Jensen, M.D. was born in Kansas City, Kansas, and earned his bachelor’s degree in Biology and Chemistry from Pittsburg State University in 1980. He graduated from Vanderbilt University School of Medicine in 1984, and remained there to complete a residency in Anatomic Pathology and a Surgical Pathology fellowship under the direction of Dr. David L. Page. Following his clinical training he accepted a Biotechnology Training fellowship at the National Cancer. He returned to Vanderbilt in 1991 and was appointed an Assistant Professor in the Departments of Pathology and Cell Biology. In 1993 Dr. Jensen was appointed as an investigator in the Vanderbilt-Ingram Cancer Center and assumed the management of the Human Tissue Acquisition and Pathology Shared Resource. Dr. Jensen was promoted to Associate Professor of Pathology and Cell Biology in 1996, and was appointed as an Associate Professor of Cancer Biology in 2001. In 2004 Dr. Jensen returned home to Kansas and was appointed the William R. Jewell, M.D. Distinguished Kansas Masonic Professor, the Director of The University of Kansas Cancer Center, the Director of the Kansas Masonic Cancer Research Institute, Professor of Pathology and Laboratory Medicine, and Professor of Anatomy and Cell Biology at the University of Kansas Medical Center. Since becoming director of the cancer center in 2004, he has recruited a world-class leadership team and successfully led that team in achieving designation for The University of Kansas Cancer Center as a National Cancer Institute designated cancer center.
Page joined The University of Kansas Hospital as vice president for Organizational Improvement in 1996. He later became the hospital’s chief operating officer and in July 2007, was selected as president and CEO. Page serves on the board of directors for the University HealthSystem Consortium, Greater Kansas City Chamber of Commerce, Kansas Hospital Association and the Kansas City Metropolitan Healthcare Council & Missouri Hospital Association’s District 2.